Alcoholism Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers
A total of at least 48 healthy subjects with a history of social drinking will be recruited
into this single-centre, randomized, double-blind, cross-over study. Subjects will be
genetically stratified to result in equal numbers of A118G 'AA' homozygotes (n=24) and A118G
'G' carriers (n=24).
Subjects will participate in all three treatment periods and will be randomized to receive
each of the following for 5 days: Treatment A: Placebo, Treatment B: Naltrexone (NTX) 50 mg
once daily (25 mg once daily for the first two days) and Treatment C: GSK1521498 10 mg once
daily. A washout period will be of at least 14 days between treatments. Subjects will return
for a follow-up visit 7-10 days after the final treatment session washout period has been
completed.
Subjects will attend the clinical research unit on days 1, 2, 3, 4 and 5 to monitor safety
and tolerability for both drugs. Subjects will attend the clinical unit on days 4 and 5 for
a two day assessment, using a series of pharmacodynamic measurements known to be sensitive
to the effects of GSK1521498 and/or NTX: Functional brain response to alcohol and food cues;
plasma cortisol; hedonic and consummatory eating behaviors; subjective response to an
ethanol challenge; experimental pain threshold; and cognitive tests of attention bias
towards alcohol and food cues.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
| Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
| Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
| Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
| Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
| Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
| Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
| Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
| Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
| Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
| Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
| Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
| Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
| Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
| Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
| Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
| Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
| Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
| Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 | |
| Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 |